These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 21972433)

  • 21. Influence of alternative thresholds for initiating HIV treatment on quality-adjusted life expectancy: a decision model.
    Braithwaite RS; Roberts MS; Chang CC; Goetz MB; Gibert CL; Rodriguez-Barradas MC; Shechter S; Schaefer A; Nucifora K; Koppenhaver R; Justice AC
    Ann Intern Med; 2008 Feb; 148(3):178-85. PubMed ID: 18252681
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modeling CD4+ cell count increase over a six-year period in HIV-1-infected patients on highly active antiretroviral therapy in Senegal.
    De Beaudrap P; Etard JF; Diouf A; Ndiaye I; Guèye NF; Guèye PM; Sow PS; Mboup S; Ndoye I; Ecochard R; Eric D;
    Am J Trop Med Hyg; 2009 Jun; 80(6):1047-53. PubMed ID: 19478274
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study.
    García F; Romeu J; Grau I; Sambeat MA; Dalmau D; Knobel H; Gomez-Sirvent JL; Arrizabalaga J; Cruceta A; Clotet BG; Podzamczer D; Pumarola T; Gallart T; O'Brien WA; Miró JM; Gatell JM
    AIDS; 1999 Dec; 13(17):2377-88. PubMed ID: 10597779
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts > or =200 cells/mm3.
    Lapadula G; Torti C; Maggiolo F; Casari S; Suter F; Minoli L; Pezzoli C; Di Pietro M; Migliorino G; Ouiros-Roldan E; Ladisa N; Sighinolfi L; Costarelli S; Carosi G;
    Antivir Ther; 2007; 12(6):941-7. PubMed ID: 17926648
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Total lymphocyte count and hemoglobin combined in an algorithm to initiate the use of highly active antiretroviral therapy in resource-limited settings.
    Spacek LA; Griswold M; Quinn TC; Moore RD
    AIDS; 2003 Jun; 17(9):1311-7. PubMed ID: 12799552
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized controlled trial of a protease inhibitor (saquinavir) in combination with zidovudine in previously untreated patients with advanced HIV infection.
    Vella S; Lazzarin A; Carosi G; Sinicco A; Armignacco O; Angarano G; Andreoni M; Tambussi G; Chiodera A; Floridia M; Scaccabarozzi S; Facey K; Duncan I; Boudes P; Bragman K
    Antivir Ther; 1996 Aug; 1(3):129-40. PubMed ID: 11322246
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection.
    Hecht FM; Wang L; Collier A; Little S; Markowitz M; Margolick J; Kilby JM; Daar E; Conway B; Holte S;
    J Infect Dis; 2006 Sep; 194(6):725-33. PubMed ID: 16941337
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative effectiveness of dynamic treatment regimes: an application of the parametric g-formula.
    Young JG; Cain LE; Robins JM; O'Reilly EJ; Hernán MA
    Stat Biosci; 2011 Sep; 3(1):119-143. PubMed ID: 24039638
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Making sense of side effects.
    Cocohoba J
    BETA; 2011; 23(4):19-29. PubMed ID: 22567824
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness of antiretroviral therapy in HIV-infected children under 2 years of age.
    Penazzato M; Prendergast A; Tierney J; Cotton M; Gibb D
    Cochrane Database Syst Rev; 2012 Jul; (7):CD004772. PubMed ID: 22786492
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Demystifying optimal dynamic treatment regimes.
    Moodie EE; Richardson TS; Stephens DA
    Biometrics; 2007 Jun; 63(2):447-55. PubMed ID: 17688497
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial.
    Gulick RM; Ribaudo HJ; Shikuma CM; Lalama C; Schackman BR; Meyer WA; Acosta EP; Schouten J; Squires KE; Pilcher CD; Murphy RL; Koletar SL; Carlson M; Reichman RC; Bastow B; Klingman KL; Kuritzkes DR;
    JAMA; 2006 Aug; 296(7):769-81. PubMed ID: 16905783
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cohort Profile: French hospital database on HIV (FHDH-ANRS CO4).
    Mary-Krause M; Grabar S; Lièvre L; Abgrall S; Billaud E; Boué F; Boyer L; Cabié A; Cotte L; De Truchis P; Duval X; Duvivier C; Enel P; Gasnault J; Gaud C; Gilquin J; Guiguet M; Katlama C; Khuong-Josses MA; Lacombe JM; Lang S; Lascaux AS; Launay O; Mahamat A; Matheron S; Meynard JL; Pavie J; Pilorgé F; Piroth L; Poizot-Martin I; Potard V; Pradier C; Reynes J; Rouveix E; Selinger-Leneman H; Simon A; Tattevin P; Tissot-Dupont H; Viard JP; Viget N; Costagliola D
    Int J Epidemiol; 2014 Oct; 43(5):1425-36. PubMed ID: 24550249
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of repeated cycles of structured therapy interruption on the rate of recovery of CD4+ T cells after highly active antiretroviral therapy resumption.
    León A; Martinez E; Milinkovic A; Mora B; Mallolas J; Blanco JL; Larrousse M; Laguno M; Gallart T; Plana M; Gatell JM; Garcia F
    J Antimicrob Chemother; 2009 Jan; 63(1):184-8. PubMed ID: 19001447
    [TBL] [Abstract][Full Text] [Related]  

  • 35. API consensus guidelines for use of antiretroviral therapy in adults (API-ART guidelines). Endorsed by the AIDS Society of India.
    Gupta SB; Pujari SN; Joshi SR; Patel AK;
    J Assoc Physicians India; 2006 Jan; 54():57-74. PubMed ID: 16649742
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Optimal dynamic regimes: presenting a case for predictive inference.
    Arjas E; Saarela O
    Int J Biostat; 2010 Mar; 6(2):Article 10. PubMed ID: 20648215
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictive factors of treatment interruption duration in a cohort of HIV-1 infected patients with CD4 count greater than 350 cells per mm3.
    Fillaux J; Delpierre C; Alvarez M; Jaafar A; Marchou B; Massip P; Cuzin L
    Med Mal Infect; 2006 Jun; 36(6):335-9. PubMed ID: 16631330
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CD4+ cell count recovery after combined antiretroviral therapy in the modern combined antiretroviral therapy era.
    Roul H; Mary-Krause M; Ghosn J; Delaugerre C; Pialoux G; Cuzin L; Launay O; Lacombe JM; Menard A; De Truchis P; Delfraissy JF; Weiss L; Costagliola D;
    AIDS; 2018 Nov; 32(17):2605-2614. PubMed ID: 30289817
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CD4+ cell count recovery after initiation of antiretroviral therapy in HIV-infected Ethiopian adults.
    Fiseha T; Ebrahim H; Ebrahim E; Gebreweld A
    PLoS One; 2022; 17(3):e0265740. PubMed ID: 35324948
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An optimal body mass index range associated with improved immune reconstitution among HIV-infected adults initiating antiretroviral therapy.
    Koethe JR; Jenkins CA; Shepherd BE; Stinnette SE; Sterling TR
    Clin Infect Dis; 2011 Nov; 53(9):952-60. PubMed ID: 21946189
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.